A Phase 2 interventional study of Osimertinib in EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 26 sites in 5 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-10-21.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.
Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 20th largest by enrollment, is one of 13 that started in 2018, is one of 46 in phase 2, and was the 30th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
AstraZeneca · Sites in China
Ages 18+
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–99
Shanghai Chest Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, osimertinib is the treatment under test here. Read study by study →
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 52 · Phase 3 12 · Phase 4 4
First in 2013; this study’s year is marked. 13 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 51 across the 90 interventional studies. Of the 32 that completed or were terminated, 21 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 90 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 68th largest by enrollment of the 137 interventional ones that give a count, is one of 20 that started in 2018, is one of 38 in phase 2, and was the 94th registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
10 of the studies testing osimertinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05120349Phase 3AstraZenecaA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | 2027-08-02 |
| NCT04285671Jonsson Comprehensive Cancer CenterNecitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | 2026-12-02 |
| NCT04322890Hunan Province Tumor HospitalTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | 2026-12-24 |
| NCT07323641Jonsson Comprehensive Cancer CenterTelisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer | 2027-02-01 |
| NCT07485452Maastricht University Medical CenterBoosting Osimertinib Blood Brain Barrier Penetration | 2027-06 |
Add all 10 to your calendar (.ics) → With an account.
Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib.
Study design This is a phase II, open-label, single-arm tissue and plasma acquisition study assessing the efficacy, safety and underlying resistance mechanisms of osimertinib (80 mg orally, once daily) as first-line treatment in patients with locally advanced or metastatic EGFR mutation positive non-small cell lung cancer who are EGFR tyrosine kinase inhibitor treatment-naïve and eligible for first-line treatment. Participants with EGFR mutation-positive non-small cell lung cancer will be required to consent to 2 mandatory tumour biopsies to be considered for enrolment in this study. The first biopsy will be done prior to initiating treatment with osimertinib and the second biopsy will be obtained any time between Investigator assessed, Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1)-defined progression and before the start of any new anticancer treatment. A third optional biopsy may be taken during the course of treatment at the Investigator's discretion if the patient consents and if clinically feasible. Tumour tissue and plasma samples will be collected and examined for genetic and non genetic aberrations that may be important in determining response and resistance to the treatment that participants will receive as a part of their cancer care. Patients should continue on osimertinib until progression or until other treatment discontinuation criteria are met. However, if patients continue to show clinical benefit to treatment as judged by the Investigator, patients may continue to receive osimertinib beyond RECIST 1.1-defined progression. Therefore, there is no maximum duration of treatment. Tumour assessments will be performed at baseline and then every 8 weeks from study enrolment until 3.5 years, and then every 10 weeks until RECIST 1.1-defined. Patients will be followed up for a period of 28 days following discontinuation of osimertinib. Target patient population Male and female patients aged 18 years and over with locally advanced or metastatic pathologically confirmed adenocarcinoma of the lung, not amenable to curative surgery or radiotherapy. Patients will have a tumour that harbours one of the EGFR mutations known to be associated with EGFR tyrosine kinase inhibitor sensitivity, either alone or in combination with other EGFR mutations (EGFR mutation status determined by a local laboratory). Patients must be EGFR tyrosine kinase inhibitor treatment-naïve and eligible to receive first line treatment with osimertinib. Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR. Osimertinib (80 mg orally, once daily) will be administered. Doses may be reduced to 40 mg if needed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
21.Inadequate bone marrow reserve or organ function 22.Female patients who are breastfeeding 23.Patients currently receiving medications or herbal supplements known to be potent inducers of cytochrome (CYP) 3A4.
24.Patient unwilling to undergo a at the time of disease progression 25.History of to active or inactive of osimertinib or drugs with a similar chemical structure or class to osimertinib 26.Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements 27.Involvement in the planning and/or conduct of the study 28.Previous enrolment in the present study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer
Drug: Osimertinib
Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR.
Also known as: TAGRISSO, AZD9291
Proportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression
The frequency of genetic and proteomic markers at disease progression regardless of their prevalence was evaluated.
Time frame: Genetic and proteomic markers were assessed at baseline and progression (up to 5 years after baseline)
Progression Free Survival (PFS)
PFS is defined as the time from first dose of osimertinib until the date of Investigator assessed Response Evaluation Criteria in Solid Tumours (RECIST) 1.1-defined progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression.
Time frame: From date of first dose until date of progression or death (by any cause in the absence of recurrence), up to 5 years
Objective Response Rate (ORR)
ORR is defined as the number (%) of patients with at least one visit response of complete response (CR) or partial response (PR) that is confirmed at least 4 weeks later.
Time frame: From date of first dose until progression, or last evaluable assessment in the absence of progression, up to 5 years
Duration of Response (DoR)
Duration of response is defined as the time from the date of first documented response, (that is subsequently confirmed) until date of documented progression or death in the absence of disease progression, the end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response will be defined as the latest of the dates contributing towards the first visit that was CR or PR that was subsequently confirmed.
Time frame: From date of first documentation of complete/partial response until the date of progression, or last evaluable RECIST assessment for participants that did not progress within 2 missed visits of last assessment, up to 5 years
Disease Control Rate (DCR)
DCR is defined as percentage of patients with confirmed complete response, confirmed partial response or with stable disease.
Time frame: 8 weeks
Time to Treatment Discontinuation or Death (TTD)
TTD is defined as the time from the date of first dose of osimertinib to the earliest of treatment discontinuation or death.
Time frame: From date of first dose to treatment discontinuation or death (by any cause in the absence of recurrence), up to 5 years
Time to First Subsequent Therapy or Death (TFST)
TFST is defined as the time from the date of first dose of osimertinib to the earlier of the date of anticancer therapy start date following study treatment discontinuation, or death.
Time frame: From date of first dose to start of subsequent anticancer therapy or death (by any cause in the absence of recurrence), up to 5 years
PFS in Patient Subgroups Defined by Molecular Profile: Epidermal Growth Factor Receptor (EGFR) Tumor Mutation at Baseline
PFS is defined as the time from first dose of osimertinib until the date of Investigator assessed Response Evaluation Criteria in Solid Tumours (RECIST) 1.1-defined progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression. PFS was analysed in patient subgroups defined by molecular profile, including but not limited to: EGFR tumor mutation at baseline-Exon19del or L858R
Time frame: From date of first dose until date of progression or death (by any cause in the absence of recurrence), up to 5 years
PFS in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma-Derived ctDNA at Baseline
PFS is defined as the time from first dose of osimertinib until the date of Investigator assessed Response Evaluation Criteria in Solid Tumours (RECIST) 1.1-defined progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression. PFS was analysed in patient subgroups defined by molecular profile, including but not limited to: Exon19del or L858R detectable in plasma derived circulating tumour deoxyribonucleic acid (ctDNA) at baseline.
Time frame: From date of first dose until date of progression or death (by any cause in the absence of recurrence), up to 5 years
ORR in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline
ORR is defined as the number (%) of patients with at least one visit response of complete response or partial response that is confirmed at least 4 weeks later. ORR was analysed in patient subgroups defined by molecular profile: EGFR tumor mutation at baseline-Exon19del or L858R
Time frame: From date of first dose until progression, or last evaluable assessment in the absence of progression, up to 5 years
ORR in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline
ORR is defined as the number (%) of patients with at least one visit response of complete response or partial response that is confirmed at least 4 weeks later. ORR was analysed in patient subgroups defined by molecular profile: Exon19del or L858R detectable in plasma derived ctDNA at baseline.
Time frame: From date of first dose until progression, or last evaluable assessment in the absence of progression, up to 5 years
TTD in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline
TTD is defined as the time from the date of first dose of osimertinib to the earliest of treatment discontinuation or death. TTD was analysed in patient subgroups defined by molecular profile: EGFR tumor mutation at baseline-Exon19del or L858R
Time frame: From date of first dose to treatment discontinuation or death (by any cause in the absence of recurrence), up to 5 years
TTD in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline
TTD is defined as the time from the date of first dose of osimertinib to the earliest of treatment discontinuation or death. TTD was analysed in patient subgroups defined by molecular profile: Exon19del or L858R detectable in plasma derived ctDNA at baseline.
Time frame: From date of first dose to treatment discontinuation or death (by any cause in the absence of recurrence), up to 5 years
Tumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline
Tumour shrinkage is defined as the best change from baseline in the sum of diameters of target lesions, in patient subgroups defined by molecular profile: EGFR tumor mutation at baseline-Exon19del or L858R. A negative change denotes a reduction in target lesion size.
Time frame: From date of first dose until last recorded post baseline RECIST target lesion assessment scan, up to 5 years
Tumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline
Tumour shrinkage is defined as the best change from baseline in the sum of diameters of target lesions, in patient subgroups defined by molecular profile: Exon19del or L858R detectable in plasma derived ctDNA at baseline. A negative change denotes a reduction in target lesion size.
Time frame: From date of first dose until last recorded post baseline RECIST target lesion assessment scan, up to 5 years
Participants were enrolled in this study from 30 May 2018 (First subject in) and analyses presented in this results form are based on a final data cut-off of 18 July 2023 and final database lock of 15 December 2023.
| Milestone | Osimertinib 80mg |
|---|---|
| Started | 154 |
| Completed | 33 |
| Not completed | 121 |
| Withdrew: Other | 26 |
| Withdrew: Patients who are ongoing in the study at dco | 10 |
| Withdrew: Death | 40 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Physician decision | 16 |
| Withdrew: Withdrawal by subject | 27 |
The frequency of genetic and proteomic markers at disease progression regardless of their prevalence was evaluated.
| Percentage of participants | Osimertinib 80 mg |
|---|---|
| AKT2; Copy Number Alteration: Type; amplification | 2.0 (0.05 to 10.45) |
| ALK; Rearrangement | 3.9 (0.48 to 13.46) |
| APC; Copy Number Alteration; Type: loss | 2.0 (0.05 to 10.45) |
| ARAF; Copy Number Alteration; Type: amplification | 3.9 (0.48 to 13.46) |
| ASXL1; Short Variant; Type: Q588* | 2.0 (0.05 to 10.45) |
| ATRX; Short Variant; Type: P599fs*22 | 2.0 (0.05 to 10.45) |
| AXL; Copy Number Alteration; Type: amplification | 2.0 (0.05 to 10.45) |
| BCL2L2; Copy Number Alteration; Type: amplification | 3.9 (0.48 to 13.46) |
| BRAF; Rearrangement | 2.0 (0.05 to 10.45) |
| BRAF; Short variant; Type: G469A | 2.0 (0.05 to 10.45) |
| BRAF; Short variant Type: V600E | 3.9 (0.48 to 13.46) |
| CBL; Short Variant; Type: R149Q | 2.0 (0.05 to 10.45) |
| CCND1 Copy Number Alteration Type: amplification | 3.9 (0.48 to 13.46) |
| CCNE1 Copy Number Alteration Type: amplification | 5.9 (1.23 to 16.24) |
| CDK4 Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| CDK6 Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| CDKN1B Short Variant Type: S2* | 2.0 (0.05 to 10.45) |
| CDKN2A Copy Number Alteration Type: loss | 15.7 (7.02 to 28.59) |
| CDKN2A; Short Variant Type: P38L | 2.0 (0.05 to 10.45) |
| CDKN2B Copy Number Alteration Type: loss | 15.7 (7.02 to 28.59) |
| CRKL Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| CUL4A Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| DIS3 Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| EGFR Copy Number Alteration Type: amplification | 11.8 (4.44 to 23.87) |
| EGFR Rearrangement | 2.0 (0.05 to 10.45) |
| EGFR Short Variant Type: C797S | 7 (5.70 to 26.26) |
| EGFR Short Variant Type: L858R | 2.0 (0.05 to 10.45) |
| EMSY Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| ERBB2 Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| FANCG Rearrangement | 2.0 (0.05 to 10.45) |
| FGF10 Copy Number Alteration Type: amplification | 3.9 (0.48 to 13.46) |
| FGF14; Copy Number Alteration; Type: amplification | 2.0 (0.05 to 10.45) |
| FGF19 Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| FGFR1 Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| FGFR3 Rearrangement | 2.0 (0.05 to 10.45) |
| FGFR4 Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| HGF Copy Number Alteration Type: amplification | 3.9 (0.48 to 13.46) |
| HRAS Short Variant Type: Q61R | 2.0 (0.05 to 10.45) |
| IDH1 Short Variant Type: R132L | 2.0 (0.05 to 10.45) |
| IGF1R Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| IRS2 Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| KRAS Copy Number Alteration Type: amplification | 3.9 (0.48 to 13.46) |
| LYN Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| MAP2K1 Short Variant Type: E102_I103del | 2.0 (0.05 to 10.45) |
| MCL1 Copy Number Alteration Type: amplification | 5.9 (1.23 to 16.24) |
| MDM2 Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| MET Copy Number Alteration Type: amplification | 17.6 (8.40 to 30.87) |
| MTAP Copy Number Alteration Type: loss | 13.7 (5.70 to 26.26) |
| MYC Copy Number Alteration Type: amplification | 3.9 (0.48 to 13.46) |
| MYCN Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| NF1 Short Variant Type: M1I | 2.0 (0.05 to 10.45) |
| NFE2L2 Short Variant Type: D29N | 2.0 (0.05 to 10.45) |
| NFKBIA Copy Number Alteration Type: amplification | 9.8 (3.26 to 21.41) |
| NKX2-1 Copy Number Alteration Type: amplification | 9.8 (3.26 to 21.41) |
| NOTCH3 Rearrangement | 2.0 (0.05 to 10.45) |
| NTRK1 Copy Number Alteration Type: amplification | 3.9 (0.48 to 13.46) |
| PARP1 Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| PDGFRB Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| PIK3CA Short Variant Type: E542K | 2.0 (0.05 to 10.45) |
| PIM1 Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| RAD21 Copy Number Alteration Type: amplification | 3.9 (0.48 to 13.46) |
| RB1 Copy Number Alteration Type: loss | 3.9 (0.48 to 13.46) |
| RB1 Short Variant Type: Q846* | 2.0 (0.05 to 10.45) |
| RICTOR Copy Number Alteration Type: amplification | 7.8 (2.18 to 18.88) |
| SMAD4 Rearrangement | 2.0 (0.05 to 10.45) |
| SMAD4 Short Variant Type: W524L | 2.0 (0.05 to 10.45) |
| SPEN Short Variant Type: D2047fs*17 | 2.0 (0.05 to 10.45) |
| STK11 Copy Number Alteration Type: loss | 2.0 (0.05 to 10.45) |
| STK11 Short Variant Type: K269fs*18 | 2.0 (0.05 to 10.45) |
| TERC Copy Number Alteration Type: amplification | 2.0 (0.05 to 10.45) |
| TERT Short Variant Type: promoter -146C>T | 2.0 (0.05 to 10.45) |
| TET2 Short Variant Type: Q916* | 2.0 (0.05 to 10.45) |
| TET2 Short Variant Type: V1862fs*13 | 2.0 (0.05 to 10.45) |
| TP53 Short Variant Type: R213* | 2.0 (0.05 to 10.45) |
| WHSC1L1 Copy Number Alteration Type: amplification | 3.9 (0.48 to 13.46) |
| ZNF703 Copy Number Alteration Type: amplification | 3.9 (0.48 to 13.46) |
PFS is defined as the time from first dose of osimertinib until the date of Investigator assessed Response Evaluation Criteria in Solid Tumours (RECIST) 1.1-defined progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression.
| Months | Osimertinib 80 mg |
|---|---|
| Progression Free Survival (PFS) | 16.4 (12.7 to 20.3) |
ORR is defined as the number (%) of patients with at least one visit response of complete response (CR) or partial response (PR) that is confirmed at least 4 weeks later.
| Percentage of participants | Osimertinib 80 mg |
|---|---|
| Objective Response Rate (ORR) | 73.4 (65.66 to 80.17) |
Duration of response is defined as the time from the date of first documented response, (that is subsequently confirmed) until date of documented progression or death in the absence of disease progression, the end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response will be defined as the latest of the dates contributing towards the first visit that was CR or PR that was subsequently confirmed.
| Months | Osimertinib 80 mg |
|---|---|
| Duration of Response (DoR) | 18.8 (14.2 to 22.3) |
DCR is defined as percentage of patients with confirmed complete response, confirmed partial response or with stable disease.
| Percentage of participants | Osimertinib 80 mg |
|---|---|
| Disease Control Rate (DCR) | 94.8 (90.02 to 97.73) |
TTD is defined as the time from the date of first dose of osimertinib to the earliest of treatment discontinuation or death.
| Months | Osimertinib 80 mg |
|---|---|
| Time to Treatment Discontinuation or Death (TTD) | 20.0 (16.3 to 23.8) |
TFST is defined as the time from the date of first dose of osimertinib to the earlier of the date of anticancer therapy start date following study treatment discontinuation, or death.
| Months | Osimertinib 80 mg |
|---|---|
| Time to First Subsequent Therapy or Death (TFST) | 32.1 (24.0 to 47.7) |
PFS is defined as the time from first dose of osimertinib until the date of Investigator assessed Response Evaluation Criteria in Solid Tumours (RECIST) 1.1-defined progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression. PFS was analysed in patient subgroups defined by molecular profile, including but not limited to: EGFR tumor mutation at baseline-Exon19del or L858R
| Months | Exon19del | L858R |
|---|---|---|
| PFS in Patient Subgroups Defined by Molecular Profile: Epidermal Growth Factor Receptor (EGFR) Tumor Mutation at Baseline | 22.0 (16.0 to 27.6) | 12.9 (10.8 to 18.2) |
PFS is defined as the time from first dose of osimertinib until the date of Investigator assessed Response Evaluation Criteria in Solid Tumours (RECIST) 1.1-defined progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression. PFS was analysed in patient subgroups defined by molecular profile, including but not limited to: Exon19del or L858R detectable in plasma derived circulating tumour deoxyribonucleic acid (ctDNA) at baseline.
| Months | Exon19del | L858R |
|---|---|---|
| PFS in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma-Derived ctDNA at Baseline | 19.6 (12.7 to 24.0) | 13.7 (9.0 to 18.2) |
ORR is defined as the number (%) of patients with at least one visit response of complete response or partial response that is confirmed at least 4 weeks later. ORR was analysed in patient subgroups defined by molecular profile: EGFR tumor mutation at baseline-Exon19del or L858R
| Percentage of participants | Exon19del | L858R |
|---|---|---|
| ORR in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline | 82.4 (72.57 to 89.77) | 69.0 (55.46 to 80.46) |
ORR is defined as the number (%) of patients with at least one visit response of complete response or partial response that is confirmed at least 4 weeks later. ORR was analysed in patient subgroups defined by molecular profile: Exon19del or L858R detectable in plasma derived ctDNA at baseline.
| Percentage of participants | Exon19del | L858R |
|---|---|---|
| ORR in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline | 85.5 (74.22 to 93.14) | 71.7 (56.54 to 84.01) |
TTD is defined as the time from the date of first dose of osimertinib to the earliest of treatment discontinuation or death. TTD was analysed in patient subgroups defined by molecular profile: EGFR tumor mutation at baseline-Exon19del or L858R
| Months | Exon19del 80 mg | L858R |
|---|---|---|
| TTD in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline | 25.5 (19.6 to 32.1) | 16.5 (12.1 to 21.7) |
TTD is defined as the time from the date of first dose of osimertinib to the earliest of treatment discontinuation or death. TTD was analysed in patient subgroups defined by molecular profile: Exon19del or L858R detectable in plasma derived ctDNA at baseline.
| Months | Exon19del 80 mg | L858R |
|---|---|---|
| TTD in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline | 24.5 (17.8 to 29.6) | 16.5 (12.1 to 21.4) |
Tumour shrinkage is defined as the best change from baseline in the sum of diameters of target lesions, in patient subgroups defined by molecular profile: EGFR tumor mutation at baseline-Exon19del or L858R. A negative change denotes a reduction in target lesion size.
| Percentage change | Exon19del | L858R |
|---|---|---|
| Tumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline | -59.68 (-100.0 to 6.5) | -54.29 (-100.0 to 7.6) |
Tumour shrinkage is defined as the best change from baseline in the sum of diameters of target lesions, in patient subgroups defined by molecular profile: Exon19del or L858R detectable in plasma derived ctDNA at baseline. A negative change denotes a reduction in target lesion size.
| Percentage change | Exon19del | L858R |
|---|---|---|
| Tumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline | -60.80 (-100.0 to 6.5) | -58.33 (-100.0 to 7.6) |
Collected over From Day 1 to Follow-up (28 days post last dose) up to 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Osimertinib 80 mg | 40/154 (26%) | 53/154 (34.4%) | 148/154 (96.1%) |
| Event | Osimertinib 80 mg |
|---|---|
| PneumoniaInfections and infestations | 12/154 |
| SepsisInfections and infestations | 4/154 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/154 |
| Urinary tract infectionInfections and infestations | 3/154 |
| Atrial fibrillationCardiac disorders | 3/154 |
| GastritisGastrointestinal disorders | 3/154 |
| GastroenteritisInfections and infestations | 2/154 |
| HyponatraemiaMetabolism and nutrition disorders | 2/154 |
| Acute coronary syndromeCardiac disorders | 2/154 |
| Cardiac failureCardiac disorders | 2/154 |
| Event | Osimertinib 80 mg |
|---|---|
| DiarrhoeaGastrointestinal disorders | 63/154 |
| ParonychiaInfections and infestations | 36/154 |
| CoughRespiratory, thoracic and mediastinal disorders | 32/154 |
| Dry skinSkin and subcutaneous tissue disorders | 30/154 |
| Decreased appetiteMetabolism and nutrition disorders | 27/154 |
| AnaemiaBlood and lymphatic system disorders | 26/154 |
| RashSkin and subcutaneous tissue disorders | 26/154 |
| Upper respiratory tract infectionInfections and infestations | 24/154 |
| PruritusSkin and subcutaneous tissue disorders | 23/154 |
| StomatitisGastrointestinal disorders | 22/154 |
| Age, Continuous(Years) | Osimertinib 80mg |
|---|---|
| Mean | 62.7 ± 10.36 |
| Sex: Female, Male(Participants) | Osimertinib 80mg |
|---|---|
| Female | 92 |
| Male | 62 |
| Race/Ethnicity, Customized(Participants) | Osimertinib 80mg |
|---|---|
| White | 30 |
| Black or African American | 5 |
| Asian | 118 |
| Other | 1 |
| Race/Ethnicity, Customized(Participants) | Osimertinib 80mg |
|---|---|
| Hispanic | 6 |
| Not Hispanic or Latino | 148 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from May 2018 to primary completion in Sep 2023, 63 months.
Results were first posted in Sep 2024, 1 year after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 63 months is above that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osimertinib
Carcinoma, Non-Small-Cell Lung →